CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on evaluating the safety and effectiveness of LAM561, a novel anti-tumor drug, in treating pancreatic cancer. It aims to conduct preclinical studies using cell and animal models to assess LAM561's potential as a monotherapy and in combination with standard chemotherapy, addressing the urgent need f…
Pancreatic cancer is a highly aggressive type of cancer, with poor prognosis and few effective therapeutic options.
At the time of diagnosis only 20% of patients are eligible for surgery, the development of metastasis has already occurred.
The life expectancy of these patients is 6-11 months (stage3) or 2-6 months (stage IV).
Laminar Pharmaceuticals SL is pioneer in the development of bioactive molecules that act through modulation of the lipid composition of the cell membrane regulating key sig…
LAMINAR PHARMACEUTICALS SA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
